Position in NUVB
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$7,397,274
New position
Shares Held
1,302,337
first reported quarter
Ownership
0.371%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#31
of 242 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026FIRST TRUST ADVISORS LP holds $2,844,450,753 across 98 Biotechnology names. NUVB ranks #51 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
547,132 | $341,158,687 | |
| 2 | INCY |
Incyte Corp
|
1,587,996 | $180,015,226 | |
| 3 | CORT |
Corcept Therapeutics Inc
|
1,829,545 | $159,078,937 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
289,179 | $143,643,884 | |
| 5 | EXEL |
Exelixis, Inc.
|
2,543,353 | $138,383,836 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
421,534 | $126,894,380 | |
| 7 | KRYS |
Krystal Biotech, Inc.
|
324,900 | $120,755,583 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
|
482,061 | $117,994,070 |
All Filings in NUVB
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,397,274 | 1,302,337 | Shares | Sole | 2026-08-11 | |
| No filing history on record for this holder in this stock. | ||||||